Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP102 + Chemotherapy vs Chemotherapy in Adjuvant TNBC
NCT05909332Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Jun 2023; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05909332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909332.